Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats
Open Access
- 1 February 2006
- journal article
- Published by Elsevier in Kidney International
- Vol. 69 (3) , 531-537
- https://doi.org/10.1038/sj.ki.5000020
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patientsKidney International, 2005
- Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidismAmerican Journal of Kidney Diseases, 2004
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney International, 2003
- Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEXJournal of Biological Chemistry, 2003
- Mechanism of the cholesterol-lowering effect of sevelamer hydrochloride, a novel phosphate binder.Nihon Toseki Igakkai Zasshi, 2003
- Identification of a Novel Fibroblast Growth Factor, FGF-23, Preferentially Expressed in the Ventrolateral Thalamic Nucleus of the BrainBiochemical and Biophysical Research Communications, 2000
- Effect of Phosphate on Parathyroid Hormone Secretion In VivoJournal of Bone and Mineral Research, 1999
- The Role of Phosphorus in the Development of Secondary Hyperparathyroidism and Parathyroid Cell Proliferation in Chronic Renal FailureThe Lancet Healthy Longevity, 1999
- Animal Model of Adenine-Induced Chronic Renal Failure in RatsNephron, 1986